INmune Bio
INMB
INmune Bio (INMB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.05
- EPS estimate
- −$0.21
- EPS surprise
- +75.81%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.21 | −$0.05 | +75.81% | $0.00 | SEC |
| Q1 2026 | May 7, 2026 | −$0.25 | −$0.20 | +18.37% | $0.00 | SEC |
| Q4 2025 | Mar 30, 2026 | −$0.27 | −$0.20 | +26.74% | $0.00 | SEC |
| Q3 2025 | Oct 30, 2025 | −$0.32 | −$0.24 | +24.53% | $0.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.38 | −$1.05 | −173.44% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.47 | −$0.43 | +8.69% | $50,000.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.55 | −$0.40 | +26.99% | $0.00 | SEC |
| Q3 2024 | Oct 31, 2024 | −$0.51 | −$0.60 | −18.41% | $0.00 | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.63 | −$0.50 | +20.63% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.54 | −$0.61 | −14.02% | $14,000.00 | SEC |
| Q4 2023 | Mar 28, 2024 | −$0.43 | −$0.47 | −10.15% | $25,000.00 | SEC |
| Q3 2023 | Nov 1, 2023 | −$0.39 | −$0.48 | −22.04% | $43,000.00 | SEC |
| Q2 2023 | Aug 7, 2023 | −$0.40 | −$0.36 | +9.21% | $46,000.00 | SEC |
| Q1 2023 | May 3, 2023 | −$0.02 | −$0.36 | −1700.00% | $38,000.00 | SEC |
| Q4 2022 | Mar 2, 2023 | −$0.49 | −$0.32 | +34.02% | $94,000.00 | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.53 | −$0.43 | +18.10% | $98,000.00 | — |
| Q2 2022 | Aug 3, 2022 | −$0.49 | −$0.38 | +21.86% | $16,000.00 | — |
| Q1 2022 | May 5, 2022 | −$0.57 | −$0.39 | +31.11% | $163,000.00 | — |
| Q4 2021 | Mar 3, 2022 | −$0.58 | −$0.57 | +0.96% | $183,500.00 | — |
| Q3 2021 | Nov 3, 2021 | −$0.36 | −$0.55 | −51.64% | $14,000.00 | — |
Quarterly revenue
Frequently asked questions
When did INmune Bio (INMB) last report earnings?
INmune Bio last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did INMB beat earnings estimates?
Yes. INmune Bio reported EPS of −$0.05 for Q2 2026 against a −$0.21 estimate — a 75.81% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.